Total returns on $1000
1Y
- 3M
- 6M
- 1Y
- 3Y
- 5Y
Fund/benchmark | Change | |
---|---|---|
Price | RTW Biotech Opportunities Ltd (Ordinary Share) | +24.00% |
NAV | RTW Biotech Opportunities Ltd (Ordinary Share) | +7.74% |
Morningstar's Benchmark | (Russell 2000 Biotech Growth) 50.000% + ( Nasdaq Biotechnology Index) 50.000% | -- |
Announcements
- Total Voting Rights
- Monthly Valuation Update and Factsheet
- Positive Data Announcement - Avidity Biosciences
- Portfolio Company Numab Therapeutics Update
- Transaction in Own Shares
- Director Declaration
- Holding(s) in Company
- Cancellation of Own Shares
- Result of AGM
- Additional Investment in Lycia Therapeutics
More ▼
Key statistics
As of last trade RTW Biotech Opportunities Ltd (RTW:LSE) traded at 1.54, -4.06% below its 52-week high of 1.60, set on Jun 17, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Shares outstanding | 335.71m |
---|---|
Market cap | 518.68m USD |
Total assets | 607.64m USD |
Total expense ratio | 1.97% |
High | 1.53 |
Low | 1.52 |
Previous close | 1.53 |
Average volume | 106.78k |
---|---|
YTD Change | +9.45% |
Beta | 0.6134 |
Diluted NAV (est) | 1.81 |
Diluted NAV (last pub) | 1.81 |
Premium/Discount | -15.47% |
Net Gearing | 0.00% |
Data delayed at least 20 minutes, as of Jul 02 2024 13:39 BST.
More ▼